The “gene dosage effect” hypothesis versus the “amplified developmental instability” hypothesis in Down syndrome
Two hypotheses exist to explain the Down syndrome (DS) phenotype. The “gene dosage effect” hypothesis states that the phenotype is a direct result of the cumulative effect of the imbalance of the individual genes located on the triplicated chromosome or chromosome region. In a nut shell, the phenotype results directly from the overexpression of specific chromosome 21 genes. The “amplified developmental instability” hypothesis contends that most manifestations of DS may be interpreted as the results of a non-specific disturbance of chromosome balance, resulting in a disruption of homeostasis. This hypothesis was proposed in an attempt to explain the similarities between the phenotypes of different aneuploid states and the observation that all of the phenotypic traits in DS are also seen in the general population but at lower frequency, with less severity and usually only present as a single trait. Herein, we review recent data and present evidence to support the theory that the phenotypic traits of aneuploid syndromes, and DS in particular, result from the increased dosage of genes encoded on the triplicated chromosome.
KeywordsDown Syndrome Klinefelter Syndrome Gene Dosage Effect Developmental Instability Ts65Dn Mouse
Unable to display preview. Download preview PDF.
- Davisson MT, Schmidt C, Reeves RH, Irving NG, Akeson EC, Harris BS, Bronson RT (1993) Segmental trisomy as a mouse model for DS. In: Epstein CJ (ed) The pheno-typic mapping of Down syndrome and other aneuploid conditions. John Wiley, New York, pp 117–133Google Scholar
- Greber-Platzer S, Schatzmann-Turhani D, Wollenek G, Lubec G (1999) Evidence against the current hypothesis of “gene dosage effects” of trisomy 21: Ets-2, encoded on chromosome 21 is not overexpressed in hearts of patients with Down Syndrome. Biochem Biophys Res Commun 254: 395–399PubMedCrossRefGoogle Scholar
- Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of DS. Proc Natl Acad Sci USA 93: 13333–13338PubMedCrossRefGoogle Scholar
- Jones KL (ed) (1988) Smith’s recognizable patterns of human malformation, 4th ed. WB Saunders, PhiladelphiaGoogle Scholar
- Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, Gos A, Nestadt G, Wolyniec PS, Lasseter VK, Eisen H, Childs B, Kazanian HH, Kucherlapati R, Atonarakis SE, Pulver AE, Housman (1995) Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA 92: 7612–7616PubMedCrossRefGoogle Scholar
- Mueller RF, Young ID (1998) Chromosome disorders. In: Emery’s Elements of Medical Genetics. Churchill Livinstone, pp 245–264Google Scholar
- Oster-Granite ML, Lacey-Casem ML (1995) Neurotransmitter alterations in the trisomy 16 mouse: a genetic model system for studies of Down syndrome. MRDD Res Rev 1: 227–236Google Scholar
- Satge D, Sasco AJ, Carlsen NL, Stiller CA, Rubie H, Hero B, de Bernardi B, de Kraker J, Coze C, Kogner P, Langmark F, Hakvoort-Cammel FG, Beck D, von der Weid N, Parkes S, Hartmann O, Lippens RJ, Kamps WA, Sommelet D (1998b) A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res 58: 448–452PubMedGoogle Scholar
- Smith DJ, Stevens ME, Sudanagunta SP, Bronson RT, Makhinson M, Watabe AM, O’Dell TJ, Fung J, Weier HU, Cheng JF, Rubin EM (1997) Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet 16: 28–36PubMedCrossRefGoogle Scholar